Association between serum 25-hydroxyvitamin D concentrations and prevalence of metabolic syndrome

Adv Med Sci. 2016 Sep;61(2):219-223. doi: 10.1016/j.advms.2016.01.002. Epub 2016 Feb 2.

Abstract

Purpose: There is now good evidence that 25-hydroxyvitamin D (25OHD) status may have an important impact on the development and progression of cardiovascular disease. Because of the potential involvement of vitamin D deficiency in blood pressure control and immune responses, we aimed to investigate whether there was a relationship between 25OHD status and the prevalence of metabolic syndrome in an Iranian population.

Material/methods: The study was carried out on a sample of 846 subjects [357(42.19%) males and 489(57.80%) females], derived from MASHAD STUDY. Serum 25OHD levels were measured using a competitive electroluminescence protein binding assay. Anthropometric indices were measured using standard protocols.

Results: Serum 25OHD was 12.7 (6.8-18.4) ng/ml in the metabolic syndrome (MetS) group and 14.1 (8.8-19.0) ng/ml in the group without metabolic syndrome (P=0.43). The frequency of vitamin D deficiency was 80.7% and 79.0% in subjects with or without metabolic syndrome in Iranian population.

Conclusions: We found no significant difference in serum 25OHD concentrations between individuals with or without MetS and no significant linear relationship between serum 25OHD and several CVD risk factors.

Keywords: 25OHD; Iran; Vitamin D deficiency.

MeSH terms

  • Adiposity
  • Body Mass Index
  • Female
  • Humans
  • Linear Models
  • Male
  • Metabolic Syndrome / blood*
  • Metabolic Syndrome / epidemiology*
  • Middle Aged
  • Multivariate Analysis
  • Prevalence
  • Triglycerides / blood
  • Vitamin D / analogs & derivatives*
  • Vitamin D / blood

Substances

  • Triglycerides
  • Vitamin D
  • 25-hydroxyvitamin D